Skip to content
Open access

Simplifying meal bolusing with Omnipod 5: real-world outcomes to support simplified user-initiated insulin dosing strategies in managing type 1 or type 2 diabetes.

Jul 2026 · Diabetes Research and Clinical Practice · Vol 239, pp. 113450 · 0 citations · 33 references
Medicine

TL;DR

Glycemic outcomes with simplified bolusing were non-inferior to carbohydrate counting, suggesting carbohydrate counting ability should not affect AID access.

Abstract

Aims

Automated insulin delivery (AID) systems typically require user‑initiated meal boluses. This study leveraged real-world data from Omnipod® 5 Automated Insulin Delivery System users to evaluate whether glycemic outcomes using simplified meal bolusing were non-inferior to carbohydrate counting.

Methods

A retrospective analysis of Omnipod 5 users in the US, UK, France, and Germany from 01/01/25 - 31/03/25 was conducted. Carbohydrate counting or simplified bolusing categorization was based on the proportion of boluses that used each individual's top five carbohydrate entries. The primary comparison used quantile regression and adjusted for users' characteristics and device settings/usage.

Results

The overall cohort included 195,529 individuals (92 % T1D). In T1D, simplified bolusing was associated with 2.5 % lower time in range (TIR) 70-180 mg/dL, 0.19 % lower time below range (TBR) < 70 mg/dL, and 5 mg/dL higher mean glucose compared with carbohydrate counting. All endpoints met noninferiority, with similar findings across age groups and countries. In T2D, differences were - 1.7 % for TIR, -0.05 % for TBR, and + 4 mg/dL for mean glucose, also meeting noninferiority. Among those using optimized settings and expected use patterns, T1D maintained noninferiority and T2D met noninferiority for TBR only.

Conclusions

Glycemic outcomes with simplified bolusing were non‑inferior to carbohydrate counting, suggesting carbohydrate counting ability should not affect AID access.

Read PDF

Similar papers

Jul 2026

A Simple Meal Bolus Strategy is Effective in Adolescents and Young Adults with Type 1 Diabetes on Multiple Automated Insulin Delivery Systems.

BACKGROUND Carbohydrate counting (CC) is challenging and may be a barrier to automated insulin delivery (AID) use. Given the ability of AID to modulate insulin delivery, a simpler meal bolus strategy may be adequate for glycemic management. METHODS Participants aged 14-26 using AID were enrolled in a randomized cross...

Alexandra Sawyer, Lindsey Towers, Samantha Lange et al. · 0 citations
Open access Jul 2026

Postprandial Glycemic Control With Automated Insulin Delivery With Control‐IQ Technology: The Impact of Meal Composition

To evaluate the efficiency of the AID system with Control‐IQ technology and carbohydrate counting (CHC)–based premeal bolus to control postprandial glucose (PPG) after mixed meals with different macronutrient compositions in adolescents with type 1 diabetes (T1D).

M. Marigliano, C. Piona, Elisa Morotti et al. · 0 citations
Aug 2026

Continuous Glucose Monitoring and Automated Insulin Delivery in Infants with Type 1 Diabetes: Real-World Evidence to Support Future International Guidelines.

CGM is safe in very young children, with AID systems proving superior to traditional therapy, and real-world evidence supports incorporating AID consideration into future international guidelines from the time of pediatric diagnosis.

M. Marigliano, A. Scaramuzza, C. Arnaldi et al. · 0 citations
Open access Aug 2026

Insulin delivery characteristics and glycemic control in older adults with type 1 diabetes using the Minimed™ 780G system: a real-world analysis

While the MiniMed™ 780G AID system use is associated with low CGM-derived hypoglycemia exposure and highly effective glycemic control, regardless of customized settings, superior glycemic control is associated with a higher proportion of user-initiated manual boluses.

Š. Volčanšek, P. Vidmar, A. Janež et al. · 0 citations
Open access Aug 2026

Extended Use of the Omnipod 5 Automated Insulin Delivery System in Adults With Type 1 Diabetes: 12‐Month Extension of a Randomized Controlled Trial

The Omnipod 5 Automated Insulin Delivery (AID) System is safe and effective for individuals managing Type 1 diabetes (T1D). Longer‐term studies may provide additional evidence of sustained effectiveness and safety of AID system use in T1D.

Éric Renard, Ruth S. Weinstock, A. Penfornis et al. · 0 citations
Open access Jul 2026

Effect of Active Insulin Time and Glycemic Targets on Automatic Correction Bolus Delivery.

Active insulin time is a key modifiable parameter influencing AB delivery and glycemic outcomes, and shorter AIT settings were associated with increased AB administration and improved TIR, whereas glucose target settings had no significant impact on these outcomes.

Giuseppe Papa, R. Cannarella, C. Gusmano et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.